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Abstract: Behçet’s disease (BD) is a chronic inflammatory disease of unknown aetiology characterized by recurrent oral, 
genital aphthous ulcerations, uveitis, skin lesions and other multisystem affections associated with vasculitis. Different 
types of vessels, predominantly veins, can be affected in BD. The frequency of vascular lesions in BD, such as superficial 
and deep venous thromboses, arterial aneurysms and occlusions, ranges between 7-29%.  
In  this  review,  various  factors  of  thrombogenesis  in  BD,  particularly  pro-  and  antithrombotic  endothelial  and  non-
endothelial factors, factors of coagulation, platelet activation and rheological changes are presented and discussed from 
positions of Virchow’s triad of venous thrombosis. 
Despite advances in understanding of thrombogenesis in BD, still many issues of diagnosis and targeted preventive and 
therapeutic measures remain unresolved. Further studies are needed to clarify the pathobiology of BD-related thrombosis 
and to provide the clinicians with recommendations over the utility, safety and effectiveness of the antithrombotic therapy 
in BD. 
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INTRODUCTION 
  Behçet’s disease (BD) is a chronic systemic disorder of 
unknown  etiology  characterized  by  recurrent  oral  and/or 
genital aphthous ulcerations, uveitis and skin lesions. Clini-
cal presentation of this disorder is multifaceted and includes 
articular, central nervous system, gastrointestinal, renal, uro-
genital, pulmonary and cardiovascular manifestations, all of 
which  are  associated  with  systemic  vasculitis,  a  pivotal 
pathophysiological feature of BD [1-4]. Recently, BD was 
classified into a group of auto-inflammatory disorders, shar-
ing some common innate immune and genetic mechanisms 
of  dysregulation  of  inflammation  [5,  6],  which  can  cause 
endothelial damage, activation of coagulation and thrombo-
sis, and underlie vascular morbidity and mortality [7, 8]. 
  Linked to  the predisposing genetic and, possibly, envi-
ronmental  factors,  cardiovascular  pathology  in  BD  repre-
sents  a  unique  spectrum  of  inflammatory,  thrombotic  and 
aneurysmatic disorders. Importantly, vessels of any size and 
type  can  be  affected,  with  venous  pathology  being  recog-
nized as a hallmark of the disease [9, 10]. The frequency of 
vascular  involvement  in  BD  (superficial  and  deep  venous 
thromboses, arterial aneurysms, occlusions) ranges between 
7-29% [9]. In a large observational study, it was shown that  
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about one quarter of patients with BD present with vascular 
involvement,  of  whom,  only  12%  with  arterial  pathology 
[11]. Though venous thrombosis of the lower extremities is 
thought to be the most frequent type of vascular pathology in 
BD, with the advent of new diagnostic techniques, such as 
magnetic  resonance  imaging,  thromboses  of  other  venous 
sites have been identified and reported in a series of recent 
observations (e.g. in superior and inferior vena cava, coro-
nary, portal, renal, pulmonary veins) [12-15]. Aneurysmatic, 
pseudoaneurysmatic and thrombotic affections of large- and 
medium-size  arteries,  right-sided  intracardiac  thrombotic 
masses  have  also  been  reported,  indicating  complexity,  
life-threatening  nature  of  thrombocoagulopathy  in  BD  and 
importance  of  complex  primary  and  secondary  prevention 
[16-18].  
  In clinical practice, especially in the debut of BD, diag-
nosis and treatment of thrombosis is a challenge, requiring 
careful consideration of multiple thrombophilic factors and 
limited therapeutic options [19]. Based on experts’ opinion, 
tight immunosuppressive therapy is, nowadays, a prerequi-
site of anti-thrombotic measures in BD. Anti-platelet therapy 
with aspirin is used in the most cases without major adverse 
effects.  Experts,  however,  expressed  caution  over  the  use  
of  anticoagulants,  which  can  cause  major  bleedings  (e.g. 
massive pulmonary haemorrhage from affected vessels) [1]. 
  BD  with  its  well-known  tendency  towards  thrombosis 
and vasculopathy can serve as a clinical model of inflamma-
tion-related  thrombosis.  In  this  regard,  investigation  of  
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factors and mechanisms involved in thrombosis in BD may 
have  far-reaching  implications  for  the  whole  group  of  
auto-inflammatory  disorders  and  cardiovascular  prevention 
in the general population [20]. 
  The  aim  of  this  review  is  to  present  some  factors  
involved in thrombocoagulation in BD.  
THROMBOGENESIS IN BD  
  Thrombogenesis in BD can be best viewed through the 
concept of Virchow’s triad of venous thrombosis. Based on 
this concept, thrombus formation requires a combination of 
at least 2 out of 3 pathological components (abnormal blood 
flow,  abnormal  vessel  wall,  abnormal  blood  constituents) 
[21]. From this standpoint, BD can be viewed as a clinical 
model of venous  thromboembolism. Abnormal blood flow 
due to the disturbances in microcirculation, increased blood 
viscosity are often coexisting with endothelial dysfunction, 
arterial  aneurysms,  venous  varices,  and  numerous  proin-
flammatory  and  prothrombotic  changes  of  blood  constitu-
ents. Direct damage of the endothelium, from one side, and 
vasculitis of vasa vasorum (more  correctly, perivasculitis), 
from the other, cause destruction of vascular elastic struc-
tures and lead to aneurysm formation, further disrupt blood 
flow. Relapses of phlebitis with venous thrombosis eventu-
ally lead to post-thrombophlebitic syndrome with sustaining 
venous blood flow abnormalities. 
Endothelial Factors 
  It is well known that in physiological conditions pro- and 
anti-coagulant endothelial activities are well balanced. Endo-
thelial cell injury activates coagulation cascade by exposing 
subendothelial collagen, by releasing pro-coagulant endothe-
lial agents, such as tissue factor (TF), von Willebrand factor 
(vWF), E-selectin, P-selectin and other adhesion molecules, 
thromboxane A2 (TxA2), the type-1 inhibitor of plasmino-
gen activators (PAI-1), platelet activator factor (PAF), and 
by reducing activity of anti-thrombotics, such as prostacyclin 
(PGI2), nitric oxide (NO),  thrombomodulin, tissue plasmi-
nogen activator (t-PA), urokinase-type plasminogen activator 
(u-PA), tissue factor pathway inhibitor (TFPI). 
  In a series of case-control studies, elevated levels of cir-
culating  vWF,  a  large  multimeric  glycoprotein,  that  binds 
and  protects  Factor  VIII  from  degradation,  and  facilitates 
platelet adhesion, were found in patients with BD. Levels of 
vWF  were  especially  high  in  those  with  thrombosis,  who 
were  also  found  to  have  highest  levels  of  t-PA,  a  serine-
protease  responsible  for  clot  destruction.  All  these  shifts 
were triggered by endothelial damage [22-27]. 
  Reduced  levels  of  thrombomodulin,  an  endothelial 
membrane protein and co-factor of anticoagulant protein C, 
were  shown  to  be  associated  to  an  increased  risk  of 
thrombosis in BD [28, 29]. 
  Tissue factor pathway inhibitor (TFPI) is another endo-
thelial protein, which reversibly inhibit Factor Xa (Xa) and 
thrombin (Factor IIa). Depletion of endothelial TFPI in BD 
was found in one study [30], while another study reported its 
elevation  [31].  This  discrepancy  is,  probably,  due  to 
laboratory  measurements  undertaken  at  different  stages  of 
disease activity. 
  An enhanced expression of E-selectin, adhesion molecule 
produced by endotheliocytes, was found in patients with BD 
with endothelial alterations at different sites (e.g. inflamed 
conjunctiva,  erythema  nodosum),  and  was  associated  with 
disease  activity  [32-37].  Immunosuppressive  therapy  was 
shown to reduce E-selectin levels in BD [37, 38]. It was also 
found that overexpression of E-selectin in BD is strongly and 
positively correlated with acute-phase reactants, such as C-
reactive protein (CRP) [39]. 
  Diminished production of nitric oxide (NO) by endothe-
lial cells, known to reflect endothelial microvascular func-
tion, was found in patients with BD in some [40-43], but not 
all  studies  [44-46].  Production  of  NO  and  its  release  into 
circulation can be impaired because of ongoing inflamma-
tion and oxidative stress, a crucial pathophysiological com-
ponent of active BD [47, 48]. Reduced bioavailability of NO 
may predispose to enhanced platelet aggregation eventually 
leading  to  thrombotic  complications  [47].  Genetic  factors, 
namely single nucleotide polymorphisms of endothelial NO 
synthase  (eNOS),  can  underlie  endothelial  dysfunction  in 
BD. In fact, Glu298Asp polymorphism in exon 7 of eNOS 
associated  to  endothelial  dysfunction,  may  explain  the  
susceptibility of certain ethnic background to BD [49-52]. 
  Another product of endothelial  cells, endothelin-1,  is a 
potent vasoconstrictor which antagonizes the effects of NO. 
Its involvement in vascular inflammation deteriorates vascu-
lar functions and leads to thrombosis. In patients with BD, 
high  levels  of  this  protein  were  found  in  association  with 
disease activity and retinal vein occlusion [53-56]. 
  Vascular endothelial growth factor (VEGF) is a marker 
of angiogenesis and endothelial dysfunction, which is pro-
duced  by  endothelial  and  some  other  cells  in  response  to 
ischemia  [57,  58].  In  several  small  case-control  studies, 
over-expression  of  VEGF  was  found  in  patients  with  BD 
[59-64], mainly during the active stage of the disease, in the 
case of ocular involvement and acute thrombosis. Attempts 
were made to associate VEGF gene polymorphisms with the 
development of BD and retinal vasculitis in Italian [65] and 
Korean  [66]  cohorts  of  patients,  with  conflicting  results, 
probably, due to the ethnic differences. 
  TFPI is a Kunitz-type proteinase inhibitor, which is pro-
duced  by  endotheliocytes  and  released  into  the  circulation 
upon stimulation by heparin. Its main function is to antago-
nize the effects of factor VIIa, factor Xa and thrombin. In 
one study, an increase of TFPI was found in BD patients, 
reflecting defensive activation of the system of antithrombo-
sis [67]. In another study, its baseline levels in BD patients 
were normal, but the degree of stimulated by heparin release 
was lower compared with SLE patients and healthy controls 
[30]. 
Procoagulant Factors 
  Leiden  point  mutation  in  the  gene  of  Factor  V 
(Arg506Glu), causing resistance of Factor V to proteolysis 
by activated protein C, and the prothrombin gene G20210A 
mutation,  leading  to  elevation  of  prothrombin  levels,  are 
common genetic factors associated with venous thrombosis 
in the general population [68]. Given the crucial role of these 
mutations in venous thrombogenesis, it was initially thought 
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However, in a multiple series of studies on the prevalence of 
these mutations among BD patients and possible association 
with  disease  activity,  ocular  involvement,  thrombosis,  ho-
mocysteinemia, CRP and other mutations related to coagula-
tion,  the  obtained  results  were  controversial  [69-78].  For 
example, the prevalence of Factor V Leiden mutation was 
shown to vary among patients with venous thrombosis be-
tween 0 and 37.5% [69]. No association was found between 
Factor V Leiden, the prothrombin gene mutation, methyle-
netetrahydrofolate  reductase  (MTHFR)  C677T  polymor-
phism, from one side, and CRP, homocysteine, factor VIII, 
from another [70]. In a recent meta-analysis of studies on 
Factor V Leiden, the prothrombin gene, MTHFR mutations 
and venous thrombosis in BD, the prothrombin gene muta-
tion  was  found  to  be  strongly  associated  with  thrombosis 
(also after excluding results of Turkish studies) [79]. 
  High levels of factor VIII, which is intimately involved 
in the coagulation cascade, were shown to be strongly asso-
ciated with the risk of thrombosis in population-based stud-
ies [80, 81]. Importantly, factor VIII was independently as-
sociated with recurrent venous thromboembolism in non-BD 
subjects [82]. In cohorts of BD patients, the results were not 
equivocal [26, 70, 82-84], with the majority of studies, indi-
cating elevation of plasma levels of this factor, alone or in 
association with vWF, which stabilizes factor VIII and, thus, 
enhances thrombogenesis [85]. 
  Factor IX, another factor of coagulation, was found to be 
elevated in one case of a BD patient presented with intracar-
diac thrombus and pulmonary aneurysm [86]. 
  Lipoprotein (a) is a low density lipoprotein, containing 
apolipoprotein B and apolipoprotein (a). Lipoprotein (a) ex-
erts  both  atherogenic  and  anti-fibrinolytic  effects  [87-89]. 
Similar to plasminogen, lipoprotein (a) binds to fibrin [90, 
91]. Elevated levels of lipoprotein (a) in BD were found in 
the most [92-95] but not all case-control studies [96]. Based 
on the obtained data [92-95], it is possible that this lipopro-
tein plays active role in vascular involvement and thrombosis 
in BD by stimulating the release of plasminogen activator 
inhibitor-1  (PAI-1)  from  endotheliocytes,  resulting  in  hy-
pofibrinolysis. 
  Antiphospholipid antibodies promote coagulation by act-
ing  against  membranes  phospholipids,  by  binding  beta-2-
glycoprotein I, prothrombin, annexin V, activated protein C, 
protein S and cross-reacting with thrombomodulin [97-100]. 
Pro-coagulant  activity  of  these  antibodies  was  associated 
with arterial and venous thromboembolism [97].  
  Many  antiphospholipid  antibodies  were  tested  in  BD 
[101-107], and except for a few small initial studies [101, 
102],  where  elevated  levels  of  anticardiolipin  antibodies 
were associated with retinal and cerebrovascular pathology 
in BD, the majority of the studies failed to report elevation of 
antiphospholipid antibodies and association with thrombosis, 
suggesting that, unlike systemic lupus erythematosus (SLE) 
and primary antiphospholipid syndrome, in this autoinflam-
matory disorder the role of autoantibodies is insignificant. 
Anticoagulant Factors 
  Congenital deficiencies of anticoagulants, such as protein 
C,  S  (inhibitor  of  activated  factor  V  and  factor  VIII)  and  
antithrombin (inactivator of factor II and other coagulation 
factors), predispose to thrombophilia in the general popula-
tion. In BD, however, their involvement in thrombotic com-
plications is insignificant [108-110]. 
  Protein  Z  is  another  anticoagulant,  a  vitamin  K-
dependent  protein  acting  as  a  co-factor  in  the  pathway  of 
activated factor X (FXa) inhibition. In one small case-control 
study,  it  was  found  to  be  decreased  in  patients  with  BD 
without vascular involvement [111]. 
Fibrinolytic Factors 
  Decreased fibrinolysis has long been recognized as a key 
factor  implicated  in  coagulopathy  in  BD  [26,  112].  Many 
case-control studies on  t-PA in  BD yielded conflicting re-
sults,  indicating  its  decreased  [93],  increased  [28]  or  un-
changed activity [24, 73]. The majority of studies on PAI-1, 
however, found increased levels of this inhibitor of plasmi-
nogen activation in patients with BD with or without estab-
lished thrombosis [93, 113]. Another inhibitor of fibrinoly-
sis, thrombin activatable fibrinolysis inhibitor (TAFI), which 
is associated with venous thromboembolism in the general 
population, was assayed in patients with BD and found to be 
increased  in  one  study  [113].  PAI-1  and  TAFI  associated 
genetic polymorphisms were also tested in this study how-
ever there was not any association with BD.  
Markers of Platelet Activation 
  Few  studies  investigated  platelet  function  in  BD  [114-
118] and found enhanced in vitro platelet aggregation in re-
sponse to adenosine diphosphate (ADP) [114-116], impaired 
sensitivity of platelets to prostacyclin [23], overexpression of 
platelet  bound  P-selectin  [117].  Patients  with  thrombosis 
demonstrated  sustained  overexpression  of  P-selectin  and 
higher levels of platelet microparticles, and circulating mi-
croaggregates [118], which is suggestive of a role of platelets 
in thrombogenesis in BD. Importantly, in one small study, it 
also was found that the prevalence of 807TT genotype and 
807T  allele  of  the  platelet  glycoprotein  Ia  C807T/G873A 
gene polymorphism is higher in patients with BD compared 
with healthy controls, which may suggest genetically prede-
termined platelet hyperfunction in  BD [119]. It should be, 
however,  noted  that  these  data  were  not  uniformly  con-
firmed, pending further more robust investigations. 
Others Factors 
  It was suggested that disturbances in the blood rheology 
may also play a role in thrombosis due to BD. High plasma 
and blood viscosity, and enhanced erythrocyte aggregation, 
which are measures of impaired blood rheology, were noted 
in patients with BD [120, 121]. However, “blood flow ab-
normalities” in BD still need to be tested in patients with and 
without thrombosis, case-control and longitudinal studies. 
CONCLUSIONS 
  Despite  advances  in  understanding  of  diverse  mecha-
nisms of thrombogenesis in BD, there are still many unre-
solved issues of diagnosis and targeted preventive and thera-
peutic measures.  
  To date, the majority of studies on thrombosis in BD ex-
amined  this  issue  fragmentally,  concentrating  on  separate 
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nents  of  thrombosis.  Accumulated  evidence  derived  pre-
dominantly from multiple case-control studies suggests that 
all  components  of  Virchow’s  triad  of  thrombosis,  namely 
abnormal  blood  flow,  abnormal  vessel  wall  and  abnormal 
blood constituents, are present in BD (Table 1). The time has 
come to investigate all these components together in large 
prospective  cohorts of patients. It would be also useful  to 
launch  a  multinational  study,  investigating  implications  of 
diverse environmental, genetic and acquired risk factors of 
thrombosis in different ethnic inceptive cohorts of patients. 
  The  prevailing  expert’s  opinion  on  the  treatment  of 
thrombosis in BD still supports immunosuppressive agents 
and  is  cautious  over  the  use  of  anticoagulants,  such  as 
warfarin and heparin [122]. Uncertainties surround the issue 
of thrombolysis, anticoagulation and coronary angioplasty in 
acute  coronary  syndromes  in  BD  [123].  Further  studies, 
aimed to compare different antithrombotics and/or immuno-
suppressive  agents  on  large  samples,  are  warranted  to  
provide the clinician with recommendations over the safety 
and effectiveness of antithrombotic therapy in BD. 
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